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The expression pattern of small nucleolar and small Cajal
body-speciﬁc RNAs characterizes distinct molecular subtypes
of multiple myeloma
D Ronchetti1, K Todoerti1, G Tuana2, L Agnelli1,2, L Mosca1, M Lionetti1,2, S Fabris1, P Colapietro3, M Miozzo4,5, M Ferrarini6, P Tassone7
and A Neri1,2
Small nucleolar RNAs (snoRNAs) and small Cajal body-speciﬁc RNAs (scaRNAs) are non-coding RNAs involved in the maturation of
other RNA molecules and generally located in the introns of host genes. It is now emerging that altered sno/scaRNAs expression
may have a pathological role in cancer. This study elucidates the patterns of sno/scaRNAs expression in multiple myeloma (MM) by
proﬁling puriﬁed malignant plasma cells from 55 MMs, 8 secondary plasma cell leukemias (sPCLs) and 4 normal controls. Overall, a
global sno/scaRNAs downregulation was found in MMs and, even more, in sPCLs compared with normal plasma cells. Whereas
SCARNA22 resulted the only sno/scaRNA characterizing the translocation/cyclin D4 (TC4) MM, TC2 group displayed a distinct
sno/scaRNA signature overexpressing members of SNORD115 and SNORD116 families located in a region ﬁnely regulated by an
imprinting center at 15q11, which, however, resulted overall hypomethylated in MMs independently of the SNORD115 and
SNORD116 expression levels. Finally, integrative analyses with available gene expression and genome-wide data revealed the
occurrence of signiﬁcant sno/scaRNAs/host genes co-expression and the putative inﬂuence of allelic imbalances on speciﬁc
snoRNAs expression. Our data extend the current view of sno/scaRNAs deregulation in cancer and add novel information to the
bio-molecular complexity of plasma cell dyscrasias.
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INTRODUCTION
Multiple myeloma (MM) is a fatal B-cell malignancy characterized
by a heterogeneous clinical course and a remarkable genomic
instability that encompasses a large array of structural and
numerical chromosomal aberrations.1 So far, many efforts have
been undertaken to deﬁne the different molecular types of MM,
with the aim to dissect the clinical heterogeneity of the disease,
identify patients at higher risk of progression or relapse and
provide insights for the development of more effective
therapeutic regimens. Furthermore, global gene expression
proﬁling of puriﬁed myeloma cells identiﬁed peculiar tumor-
associated transcriptional proﬁles, which are able to discriminate
between normal and tumor phenotypes, or speciﬁcally associated
with distinct MM molecular subtypes with different prognosis.2,3
In recent years, the increasing discovery of non-coding RNAs
(ncRNAs) have changed the landscape of cancer biology. ncRNAs
are functional transcripts that do not code for proteins, however,
they have a major role in regulating almost every level of gene
expression. In addition to highly abundant and functionally
important transfer and ribosomal RNAs (tRNA and rRNA), ncRNAs
include a large variety of molecules such as microRNAs (miRNAs),
short interfering RNAs, piwi-associated RNAs, small nucleolar RNAs
(snoRNAs), small Cajal body-speciﬁc RNAs (scaRNAs), small nuclear
RNAs (snRNAs) and long ncRNAs that are still only partially
understood.4 Among these, miRNAs have been extensively
studied in carcinogenesis.4 In the context of MM, we and other
authors have recently shown that deregulated patterns of miRNA’s
expression are associated with distinct clinical and molecular
entities of disease, giving evidence of their pathogenetic role.5,6
snoRNAs are molecules of 60–300 nucleotides in length that
associate with speciﬁc proteins, highly conserved among eukar-
yotes, to form small nucleolar ribonucleoparticles. Two main
groups of snoRNAs have been described: the box H/ACA snoRNAs
(SNORAs), which bind conserved core box H/ACA snoRNP
proteins, such as DKC1, GAR1, NHP2 and NOP10, mainly acting
as guide RNAs in the site-speciﬁc pseudouridylation of target
rRNA; and the box C/D snoRNAs (SNORDs), which bind conserved
core box C/D snoRNP proteins, such as ﬁbrillarin, NOP56, NOP5/
NOP58 and NHP2L1, involved in 20-o-ribose methylation. The
peculiar nucleolar localization of snoRNAs provides a direct
connection with their classical function: in fact, most snoRNAs
function as guide RNAs for the post-transcriptional modiﬁcation of
ribosomal RNAs and some spliceosomal RNAs, with a few others
involved in nucleolytic processing of the original rRNA transcript.
These post-transcriptional modiﬁcations are important for the
production of efﬁcient and accurate ribosomes. Unlike snoRNAs,
scaRNAs accumulate within the Cajal bodies (conserved sub-
nuclear organelles that are present in the nucleoplasm); moreover,
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scaRNA molecules, such as U92, ACA47, ACA11, U109 and ACA57,
can possess both box C/D and box H/ACA sequence motifs,
thus guiding both the methylation and pseudouridylation of
snRNAs as reported for U85.7 sno/scaRNAs can also target other
RNAs, including snRNAs and mRNAs. However, a subgroup of so-
called ‘orphan’ sno/scaRNAs exists that lacks any apparent
complementarities to cellular RNAs and their function remains
to be clariﬁed. Notably, in vertebrates, most sno/scaRNAs reside in
the introns of protein-coding host genes and are processed out of
the excised introns.8
Experimental evidence has recently shown that sno/scaRNAs
may have malfunctioning roles in human cancers, suggesting that
they could be actively involved in tumorigenesis.9 However, data
concerning the involvement of sno/scaRNAs in cancer, and
hematological malignancies in particular, are extremely limited.
Recently, a global downregulation of snoRNAs in acute leukemia
cells when compared with non-neoplastic counterparts has been
described along with the signiﬁcant ectopic expression of
SNORD112-114 in acute promyelocytic leukemia.10 Lopez-Corral
et al.11 reported the overexpression of SNORD25, SNORD27,
SNORD30, and SNORD31 in smoldering MM patients showing a
rapid progression to symptomatic disease. Very recently, Chu
et al.12 reported the upregulation of SCARNA22 in MMs harboring
the t(4;14); notably, this scaRNA is localized within intron 18
of the WHSC1/MMSET gene involved in the translocation and
constitutively expressed in these patients. Interestingly, these
authors provided experimental evidence that SCARNA22 can
suppress oxidative stress both in vitro and in vivo, facilitate cell
proliferation and protect cells from the effects of chemotherapy,
suggesting an oncogenic role for this type of ncRNA in MM.
In the present study, we investigated the sno/scaRNA expres-
sion proﬁling in a molecularly characterized cohort of MM and
secondary plasma cell leukemia (sPCL) patients. Furthermore, sno/
scaRNA proﬁles have been correlated with the expression levels of
the respective host-genes and the allelic imbalances involving
their genomic location.
MATERIALS AND METHODS
Samples
Bone marrow specimens from 55 newly diagnosed untreated MM and 8
sPCL patients, all described in our previous reports,13–15 were obtained
during standard diagnostic procedures after informed consent in
accordance with the Institutional guidelines. The diagnosis of MM was
made according to previously described criteria.16 Plasma cells (PCs) were
puriﬁed from bone marrow samples using CD138 immunomagnetic
microbeads (MidiMACS system, Miltenyi Biotec, Auburn, CA) as
previously described.2,17 PCs from tonsils of four healthy donors were
also puriﬁed and included in the study. The purity of the positively selected
PCs was assessed by means of morphology and ﬂow cytometry and was
X90% in all the cases. The 55 MM used for microarray analysis were
representative of the major molecular characteristics of the disease. All of
the samples were characterized for the presence of the most frequent
chromosomal translocations and the ploidy status based on ﬂuorescence
in situ hybridization (FISH) evaluation criteria.18 MM samples were stratiﬁed
in ﬁve groups according to the translocation/cyclin D (TC) classiﬁca-
tion.19,20 Speciﬁcally, 12 samples were in the TC1 group, characterized by
the t(11;14) or t(6;14) translocations, with the consequent overexpression
of either cyclin D1 (CCND1) or CCND3 and a non-hyperdiploid (HD) status;
13 in the TC2, showing low-to-moderate levels of the CCND1 gene in the
absence of any primary immunoglobulin H (IGH) translocation and HD
status; 12 in the TC3, including tumors that do not fall into any of the other
groups, most of which express CCND2; 12 in the TC4, showing high CCND2
levels and the presence of the t(4;14) translocation; and 6 in the TC5,
expressing the highest levels of CCND2 in association with either the
t(14;16) or t(14;20) translocations. Deletions of chromosome 17p13, 13q14
and gain of chromosome 1q were also evaluated by FISH. Clinical and
biomolecular features concerning all the investigated patients are reported
in Supplementary Table S1.
Gene expression proﬁling
The MM-sPCL panel and tonsillar-puriﬁed PCs from four normal controls
were analyzed on the GeneChip Human Gene 1.0 ST array (Affymetrix,
Santa Clara, CA). The raw intensity expression values were processed by
Robust Multi-array Average procedure,21 with the re-annotated Chip
Deﬁnition Files from BrainArray libraries version 15.0.022 available at
http://brainarray.mbni.med.umich.edu.
Supervised analyses were carried out using the Signiﬁcant Analysis of
Microarrays software version 4.00 (excel front-end publicly available at
http://www-stat.stanford.edu/Btibs/SAM/index.html).23 The cutoff point
for statistical signiﬁcance (at a q-value 0) was determined by tuning the
D parameter on the false discovery rate and controlling the q-value of the
selected probes. Hierarchical agglomerative clustering of the most
signiﬁcant probesets found was performed adopting Euclidean and
average as distance and linkage methods, respectively. DNA-Chip
Analyzer software (dChip)24 was used to perform clustering and to
graphically represent it. Gene expression proﬁling data have been
deposited in the NCBI Gene Expression Omnibus database (GEO; http//
www.ncbi.nlm.nih.gov/geo).
Quantitative real-time PCR (QRT-PCR)
For QRT-PCR, 500 ng of the total RNA was used for reverse transcription
using random primer mix and reagents from INVITROGEN (Life Technol-
ogies, Foster City, CA). Real-time PCR was performed in triplicate using
TaqMan Non-coding RNA Assays together with the TaqMan Fast Universal
PCR Master Mix on an Applied Biosystems 7900 Sequence Detection
System (Life Technologies). All of the RNA samples were normalized on the
basis of the UBC housekeeping gene. The threshold cycle (CT) was deﬁned as
the fractional cycle number at which the ﬂuorescence passes the ﬁxed
threshold. snoRNA expression was relatively quantiﬁed using the 2DCt
method (Applied Biosystems User Bulletin No. 2) and expressed as the relative
quantity of target snoRNA normalized to the UBC housekeeping gene.
Genome-wide DNA proﬁling
Twenty-ﬁve of the 63 MM/sPCL samples proﬁled for sno/scaRNA
expression were used for genome-wide DNA analysis using Affymetrix
GeneChip Human Mapping 50K XbaI microarrays as previously reported
by us.13
Methylation analysis at 15q11 by pyrosequencing
DNA methylation was quantitated using bisulﬁte-PCR and Pyrosequencing
assays. In brief, the samples were bisulﬁte treated, and PCR ampliﬁed by
means of the PyroMark Q96 CpG Prader-Willi kit (Qiagen, Dusseldorf,
Germany), as recommended by the manufacturer. Pyrosequencing was
performed using the PyroMark 96 (Qiagen). Methylation quantiﬁcation
was performed using the provided software. The degree of methylation
was expressed as %5-methylated cytosines over the sum of methylated
and unmethylated cytosines.
Statistical analysis
Conventional statistical procedures were applied using standard packages
for R software (Kendall t correlations and Wilcoxon rank-sum tests).
Multiple-test correction has been applied in order to measure the false
discovery rate that incurred when calling the test signiﬁcant based on
P-value (q-value o0.05 as threshold).
RESULTS
Global sno/scaRNA expression proﬁling in MM patients
The expression proﬁles of sno/scaRNA genes have been investi-
gated in a panel of 55 MMs, 8 sPCLs and 4 normal tonsil PCs. MM
patients were fully representative of the different molecular
groups according to the TC classiﬁcation (see Material and
Methods). In addition, the HD status, del(13), del(17) and 1q gain
were investigated by FISH in almost all the samples (Figure 1 and
Supplementary Table S1 for further details).
Sno/scaRNA expression proﬁles were analyzed using Human
Gene 1.0 ST arrays. Oligonucleotide probes on Gene Chips were
re-mapped according to the latest human genome and tran-
scriptome information (see materials and methods) identifying
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215 human snoRNA (76 SNORA and 139 SNORD transcripts) and
17 human scaRNA genes. To determine whether the natural
grouping of global sno/scaRNA expression proﬁling could be
associated with speciﬁc molecular groups, we performed an
unsupervised analysis using conventional hierarchical agglomera-
tive clustering of the 115 snoRNAs and 13 scaRNAs whose average
change in expression levels varied at least 1.5-fold from the mean
across the data set (Figure 1). The most striking ﬁnding was that 8
of 13 TC2 patients clustered together (Figure 1, green cluster,
Po0.0001), as did 5 of 8 sPCL cases (blue cluster, P¼ 0.0006),
whereas the TC1, TC3, TC4 and TC5 samples were scattered along
the dendrogram.
Next, multiclass analysis of MM samples involving all the ﬁve TC
groups, identiﬁed a set of 14 snoRNAs and 1 scaRNA, showing
highly signiﬁcant differential expression between the groups
(at q-value¼ 0). As shown in Figure 2a, all identiﬁed ncRNAs, with
the exception of SNORD101 and SCARNA22, were found to be
upregulated in the TC2 group and partially expressed in some TC4
and TC3 patients, whereas in TC1 and TC5, they were down-
modulated (Supplementary Table S2). In addition, SCARNA22 was
selectively expressed in TC4 samples. Notably, SNOR115-7, -24, -
25, -31, -32 and SNORD116-22, -23, -25, -29 are multiple transcripts
of SNORD115 and SNORD116 families that belong to a cluster
located at 15q11. Similarly, supervised analysis comparing HD
versus not-HD cases (ﬁve HD patients harboring concurrently IGH
translocation were excluded from the analysis) revealed seven
SNORA (SNORA70D, -40, -74A, -64, -23, -22 and -68) and ﬁve
SNORD (SNORD24, -36B, -63, -36C and -D95) transcripts, all but
one (SNORA70D) upregulated in the HD setting (Supplementary
Table S3). Notably, SNORA74A, SNORD24 and SNORD36C were
also found upregulated in TC2 patients by the multiclass analysis
(see above), in all likelihood because of their representativeness
within HD cases. Furthermore, we investigated sno/scaRNA
expression in the context of other recurrent chromosomal
alterations in MM, such as del(13) and 1q gain, but no signiﬁcantly
differentially expressed sno/scaRNAs between positive and
negative patients were recognized. Finally, the comparison of
MM versus sPCL samples identiﬁed 11 differentially expressed
snoRNAs, all downregulated in sPCL patients (Figure 2b and
Supplementary Table S4).
As a ﬁnal point, the proﬁling of normal tonsils PCs provided us
some insight into the sno/scaRNA expression pattern in a putative
normal PC counterpart. In particular, compared with normal PCs, it
appears that both MM and, even more, sPCL samples exhibited
lower expression levels of the most variables sno/scaRNA genes in
our data set (Figure 1), with the exception of snoRNAs located at
15q11 region, which are overexpressed in the TC2 group (see
black boxes in Figures 1 and 2a).
QRT-PCR validation of differentially expressed snoRNAs
To validate the microarray data, the levels of SNORD8, SNORD116-
29, SNORD94 and SNORD95 were quantiﬁed in 33 samples by
QRT-PCR. As reported in Figure 3a, linear correlation analysis
indicated a good correspondence between the two techniques.
QRT-PCR results also conﬁrmed the statistically signiﬁcant and
Figure 1. Unsupervised analysis of sno/scaRNA expression profiles. Hierarchical clustering of the samples using the 128 most variable sno/
scaRNAs (patients in columns, snoRNAs in rows). sno/scaRNA expression levels in CD138-positive cells from tonsils are shown on the left. The
color scale bar represents the relative sno/scaRNA expression changes normalized by the standard deviation. The patients’ molecular
characteristics are shown above the matrix; n indicates unavailable information. Specific characteristics are enriched in colored sub-branches
(see text). Black boxes identify SNORD115 and -116 clusters at 15q11.
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speciﬁc overexpression of SNORD116-29 and SNORD8 in the TC2
group and the downregulation of SNORD94 and SNORD95 in sPCL
samples (Figure 3b).
Correlation of sno/scaRNAs expression levels with those of their
corresponding host genes
The vast majority of human sno/scaRNAs are encoded in introns of
so-called host genes, in the sense orientation, and are produced
by exonucleolytic processing of the debranched intron after
splicing.25 To assess whether deregulated sno/scaRNAs were
coordinately expressed with their host mRNAs, we investigated
the 160 sno/scaRNA-host gene couples for which the host gene
expression levels are available on Human Gene 1.0 ST arrays. Non
parametric Kendall t correlation test identiﬁed 72 snoRNAs and 7
scaRNAs whose expression levels signiﬁcantly correlated with
those of their corresponding host gene (Supplementary Table S5).
Concerning sno/scaRNAs resulting from the multiclass and two-
class analyses (Figure 2), the expression levels of SNORD36C, -63,
-95, -101, SNORA23, -40, -70D and SCARNA22 were signiﬁcantly
associated with that of their host transcripts encoding for the
ribosomal protein L7A (RPL7A, q-value¼ 2E-2), the heat shock
protein 9 (HSPA9, q-value¼ 5E-4), the receptor for activated
protein Kinase C (RACK1, q-value¼ 4E-4), the ribosomal protein
S12 (RPS12, q-value¼ 1E-3), the cytoplasmic shuttle protein
IPO7 (q-value¼ 9E-3), the TATA box-binding factor 1D (TAF1D,
q-value¼ 4.3E-13), the AKT protein phosphatase PHLPPL
(q-value¼ 2.9E-11) and MMSET (q-value¼ 1.29E-09), respectively
(Table 1).
Integrative analysis of sno/scaRNA expression proﬁles with
genome-wide copy number alterations and occurrence of loss of
heterozygositys
Next, we investigated the inﬂuence on sno/scaRNA expression of
the allelic imbalances detected by single nucleotide polymorph-
ism array analysis available in 25 of 63 cases.13 By referring to
snoRNA-LBME-database25 based on the UCSC Genome Browser
Database annotations (genome assembly NCBI36/hg18), we
inferred the DNA copy number of each sno/scaRNA locus
according to our previous report.13 The integrative analysis
identiﬁed 16 snoRNAs whose expression was signiﬁcantly
associated with their matching copy number (Kendall q-value
o0.05; Table 2, Supplementary Figure S1). Among these, we
found SNORD116-23, -25, -29 overexpressed in TC2 patients,
SNORA68 upregulated in HD samples, SNORD95 downregulated in
sPCL but upregulated in HD MM and SNORD32A downregulated
in sPCL. Notably, SNOR116-11, -23, -25, -26, -28, and -29 and
SNORD115-8 belong to the SNORD115 and SNORD116 cluster at
15q11; SNORA68, SNORD105, SNORD41 and SNORD32A are
Figure 2. Identification of sno/scaRNA signatures characterizing distinct MM genetic subgroups. (a) Heatmap of the differentially expressed
sno/scaRNAs in MM patients stratified into the five TC groups; sno/scaRNA expression levels in sPCLs and CD138-positive cells from tonsils are
shown on the left. (b) Supervised analyses identifying the snoRNAs that are differentially expressed in MM and sPCL patients; sno/scaRNA
expression levels in CD138-positive cells from tonsils are shown on the left.
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located on chromosome 19; SNORD15B is positioned at 11q13,
whereas SNORD95 is mapped at 5q35. These chromosome regions
are gained in HD patients and exhibit transcriptional imbalances,
as previously reported by us.18 Moreover, a gene-dosage effect
might also be associated with the expression of SNORD81, -75 and
-44, all of them located on chromosome 1q25, a region known to
be involved in gain/ampliﬁcation in MM.26
Conversely, no signiﬁcant correlation was identiﬁed between
sno/scaRNAs expression and the occurrence of loss of hetero-
zygosity in the same panel of cases using Wilcoxon rank-sum test
as previously described13 (data not shown).
Upregulation of SNORD115 and SNORD116 does not correlate with
altered methylation status of the imprinting center at 15q11
SNORD115 and SNORD116 are located at 15q11, in a region known
to be affected by minimal deletions involved in the Prader–Willi
syndrome (PWS).27 SNORD115 and SNORD116 are present in highly
similar multiple copies (47 and 24 copies, respectively) that are
tandemly arranged within the introns of the SNURF–SNRPN
transcript, which spans more than 460 kb and contains at least
148 exons. The expression of SNURF–SNRPN, as well as that of
several genes in this region, is ﬁnely regulated by a bipartite
imprinting center (IC) that silences most maternal genes of the
PWS critical region: owing to this imprinting, the SNURF–SNRPN
pre-mRNA is expressed only from the paternal allele.27 To test
whether the IC methylation status may contribute to the
modulated expression of SNORD115 and SNORD116 in MM, we
performed a pyrosequencing analysis of 30 MM patients (12 TC2
samples and 18 MM of other TC groups), 4 DNA from puriﬁed
peripheral T cells of paired TC2 samples and the 4 normal controls.
As shown in Figure 4, all myeloma samples displayed a signiﬁcant
IC hypomethylation compared with normal controls.
DISCUSSION
snoRNAs and scaRNAs have been found to have crucial roles in
rRNA, tRNA, snRNA as well as in mRNA biogenesis.28 More
recently, experimental evidence indicated that sno/scaRNAs may
also have important roles in human cancers.9 To the best of our
knowledge, this is the ﬁrst report describing the global expression
proﬁles of sno/scaRNAs in MM. Our results identify speciﬁc
patterns of sno/scaRNAs associated with distinct molecular types
of MM and provide novel insights into our understanding the
complex biological scenario of the disease.
Our study indicated a general pattern of downregulation of sno/
scaRNAs expression in MM and sPCL patients compared with a
non-neoplastic counterpart (Figure 1), a ﬁnding in agreement with
the recent evidence of snoRNAs global downregulation reported
in acute myeloblastic and lymphoblastic leukemias.10 This ﬁnding
is particularly striking in sPCL; in such a context, the
downregulation of SNORD32A must be noted (Figure 2b), for
which a non-canonical role in the mediation of oxidative and
endoplasmic reticulum stress-induced response pathways has
been recently reported in vitro and in mouse models.29 In this
perspective, one can speculate that SNORD32A downregulation
could be involved in the regulation of oxidative stress during
oncogenesis and might imply tumoral PCs resistance to
endoplasmic reticulum stress-induced response, as it was
recently demonstrated for SCARNA22 in myeloma cell lines.12
Surprisingly, sPCLs showed the downregulation of SNORA42,
which is located at chromosome 1q22, a region frequently
ampliﬁed in plasma cell dyscrasias. SNORA42 has been
described to act as a putative oncogene in non-small cell lung
cancer cell lines being overexpressed in association with the gain
of 1q region and positively correlated to poor survival.30 The
different patterns found in our study may suggest that some
snoRNAs could have different roles depending on the cellular
context, as largely demonstrated for miRNAs.
Despite the general pattern of downregulation observed in
myeloma cells, HD MMs upregulate speciﬁc snoRNAs. Considering
the canonical function of snoRNAs, their expression in HD tumors
may be not surprising, as this molecular group is characterized by
a global upregulation of the translational machinery, including
genes involved in protein biosynthesis, such as ribosomal proteins,
mitochondrial ribonucleoproteins or proteins acting in rRNA
processing.18 Furthermore, SNORD36C, -63, -95 and SNORA40
appear to be upregulated in HD samples in correlation with their
matched host genes RPL7A, HSPA9B, RACK1 and TAF1D,
respectively (Table 1), whose biological functions are related to
the above-mentioned processes as well.31–33 Notably, RACK1 is the
major component of translating ribosomes and it has been
reported to provide a physical and functional link between protein
kinase C signaling and ribosome activation.31 Interestingly, it has
been recently described as a pro-apoptotic gene in human breast
and colon cancer.34 Finally, the chromosomal regions where these
snoRNAs are located (see Table 1) have been previously reported
by us to be transcriptionally active or speciﬁcally downregulated
in HD patients.18 Based on these ﬁndings, it could be suggested
that snoRNAs expression in HD samples may have a role in the
overall upregulation of the translational machinery.
Interestingly, MM patients included in the TC2 group showed a
quite different signature, consisting of 14 speciﬁc snoRNAs
(Figure 2a). In particular, these patients expressed nine members
of the SNORD115 and SNORD116 snoRNA families that are
speciﬁcally expressed in the brain in mouse, while only SNORD115
Figure 3. QRT-PCR validation of snoRNA expression. For each
snoRNA, the Pearson’s correlation coefficient was calculated
between gene expression profiling data and QRT-PCR results
expressed as 2DCt (a). Box plots of snoRNAs quantified in QRT-
PCR in 33 MM-PCL cases, whose expression significantly correlated
to group membership on the basis of Wilcoxon rank-sum tests
(P-values are shown above each panel). (b) The expression levels are
represented as 2DCt.
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is strictly brain-speciﬁc in humans.35 Our study provide evidences
that, similarly to what was described for SNORD112, -113 and -114
in leukemia,10 not all the SNORD115 or SNORD116 variants have
similar expression patterns in MM, a ﬁnding that could be
consistent with the different putative targets predicted for these
SNORDs.36 Furthermore, it should be considered that the
expression of some variants of SNORD115 or SNORD116
appeared to be signiﬁcantly correlated with the DNA copy
number (Table 2). In addition, as suggested by the hypomethyla-
tion of the IC at 15q11, other mechanisms may regulate their
expression in speciﬁc MM groups. With regard to this ﬁnding, the
hypomethylation of the IC could be related to the general pattern
Table 1. Correlation of the expression level of sno/scaRNAs (resulting from supervised analyses) and corresponding host genes
snoRNA Alias Cytoband HOST GENE Kendall q-value Target RNA
SNORA23 ACA23 11p15 IPO7 9.0E-03 28S rRNA U3737 and 28S rRNA U4331
SNORA40 ACA40 11q21 TAF1D 4.3E-13 28S rRNA U4546 and 18S rRNA U1174
SNORA49 ACA49 12q24 EP400 6.0E-01 Unknown
SNORD8 mgU6-53 14q11 CHD8 3.4E-01 U6 snRNA A53
SNORD115-24 HBII-52-24 15q11 SNURF-SNRPN 5.0E-01 Serotonin receptor 5HT-2C mRNA
SNORD115-25 HBII-52-25 15q11 SNURF-SNRPN 1.2E-01 Serotonin receptor 5HT-2C mRNA
SNORD115-31 HBII-52-31 15q11 SNURF-SNRPN 3.9E-01 Serotonin receptor 5HT-2C mRNA
SNORD115-32 HBII-52-32 15q11 SNURF-SNRPN 3.8E-01 Serotonin receptor 5HT-2C mRNA
SNORD115-7 HBII-52-7 15q11 SNURF-SNRPN 1.6E-01 Serotonin receptor 5HT-2C mRNA
SNORD116-22 HBII-85-22 15q11 SNURF-SNRPN 9.0E-01 Unknown
SNORD116-23 HBII-85-23 15q11 SNURF-SNRPN 6.1E-01 Unknown
SNORD116-25 HBII-85-25 15q11 SNURF-SNRPN 4.4E-01 Unknown
SNORD116-29 HBII-85-29 15q11 SNURF-SNRPN 5.6E-01 Unknown
SNORA64 U64 16p13 RPS2 Aa 28S rRNA U4975
SNORA70D U70D 16q22 PHLPPL 3.0E-11 18S rRNA U1692
SNORD68 HBII-202 16q24 RPL13 3.0E-01 18S rRNA U428 and 28S rRNA A2388
SNORA48 ACA48 17p13 EIF4A1 Aa 28S rRNA U3797
SNORA68 U68 19p13 RPL18A Aa 28S rRNA U4393
SNORD32A U32A 19q13 RPL13A Aa 18S rRNA G1328 and 28S rRNA A1511
SNORD55 U55 1p34 RPS8 Aa 28S rRNA C2791
SNORA42 ACA42 1q22 KIAA0907 9.3E-01 8S rRNA U572 and 18S rRNA U109
SNORA60 ACA60 20q11 SNHG11 8.3E-01 18S rRNA U1004
SNORD94 U94 2p11 PTCD3 8.3E-01 U6 snRNA C62
SNORA74A U19 5q31 MATR 1.3E-01 28S rRNA U3741 and 28S rRNA U3743 and U3 snRNA U8
SNORD63 U63 5q31 HSPA9B 5.7E-04 28S rRNA A4541
SNORD95 U95 5q35 RACK1 4.2E-04 28S rRNA A2802 and 28S rRNA C2811
SNORA20 ACA20 6p25 TCP1 9.5E-02 18S rRNA U651
SNORD101 U101 6q23 RPS12 1.4E-03 Unknown
SNORA22 ACA22 7q11 CCT6P1 Aa 28S rRNA U4966 and 28S rRNA U4975
SNORD24 U24 9q34 RPL7A 3.6E-01 28S rRNA C2338 and 28S rRNA C2352
SNORD36B U36B 9q34 RPL7A 5.8E-01 18S rRNA A668
SNORD36C U36C 9q34 RPL7A 2.9E-02 28S rRNA A3703
SNORD61 U61 Xq26 RBMX 4.2E-01 18S rRNA U1442
SCARNA22 ACA11 4p16 MMSET 1.3E-09 Unknown
Abbreviations: scaRNA, small Cajal body-specific RNA; snoRNA, small nucleolar RNA. aProbe not present onto Human Gene 1.0 ST arrays; snoRNA significantly
correlating with corresponding host gene is typed in bold.
Table 2. Correlation of snoRNA expression and CN alteration
snoRNA Alias Cytoband START LOC END LOC Kendall q-value
SNORD95 U95 5q35.3 180602920 180602982 5.7E-3
SNORA68 U68 19p13.11 17834397 17834529 1.8E-2
SNORD105 U105 19p13.2 10079327 10079411 1.8E-2
SNORD116-25 HBII-85-25 15q11.2 22893902 22893995 1.8E-2
SNORD116-26 HBII-85-26 15q11.2 22895738 22895835 1.8E-2
SNORD116-28 HBII-85-28 15q11.2 22900881 22900973 1.8E-2
SNORD32A U32A 19q13.33 54685037 54685113 1.8E-2
SNORD115-8 HBII-52-8 15q11.2 22980546 22980627 2.4E-2
SNORD116-29 HBII-85-29 15q11.2 22902760 22902844 2.8E-2
SNORD81 U81 1q25.1 172099907 172099983 2.9E-2
SNORD116-11 HBII-85-11 15q11.2 22872168 22872261 3.3E-2
SNORD41 U41 19p13.13 12678263 12678332 3.9E-2
SNORD116-23 HBII-85-23 15q11.2 22888025 22888118 4.8E-2
SNORD15B U15B 11q13.4 74793113 74793258 4.8E-2
SNORD75 U75 1q25.1 172102640 172102699 4.8E-2
SNORD44 U44 1q25.1 172101727 172101789 4.9E-2
Abbreviations: CN, copy number; snoRNA, small nucleolar RNAs. snoRNAs resulting from multiclass or two-class analyses and significantly correlating with
corresponding CN are typed in bold.
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of global de-methylation described in tumors and, in particular, in
MM, as recently reported by us and others.37,38
Notably, the only scaRNA differentially expressed among the
molecular MM groups is SCARNA22, which is speciﬁcally
upregulated in patients with the t(4;14). As speciﬁed above,
SCARNA22 is located within intron 18 of the MMSET gene, which is
constitutively activated by the translocation. Therefore, as
demonstrated by the correlation analysis (Supplementary Table
S5), SCARNA22 is overexpressed in association with its host gene,
as also found in sPCLs and human MM cell lines harboring t(4;14)
(Supplementary Figure S2). This is in line with very recent
evidence of the upregulation of this scaRNA in t(4;14) patients,
suggesting a key role for this molecule in the pathogenesis of the
TC4 group of MM.12
Concerning the signiﬁcance of the sno/scaRNA expression in
MM patients, it should be considered that these molecules may
have also a role in the regulation of alternative splicing mRNAs.
This has been suggested for murine SNORD115 that has been
found to be processed to a shorter form in order to hybridize to
complementary target sequences on the HTR2C pre-mRNA for the
correct alternative splicing of the serotonin receptor mRNA.39
Furthermore, a role in the 30 processing of selected snoRNAs has
been very recently proposed for SCARNA22.12 In line with this
evidence, a similar function could be awaited for SNORD101 and
the ‘orphan’ SNORD116 variants, as predicted by the recent
available snoTARGET open source.36
In the attempt to elucidate the role of snoRNAs in cancer, it
should be considered that they may be involved in mRNA stability.
Indeed, recent studies have expanded the range of regulatory
non-coding RNAs, based on the evidence of human miRNA
precursors resembling SNORA or SNORD genes or snoRNAs
showing miRNA-like functions.40–43 Although miRNAs and
snoRNAs are currently believed to be generated by different
cellular pathways and to function in different cellular
compartments, at least some of these molecules seem to have
dual functions; that is, the same transcript can give rise both to a
snoRNA and—probably through subsequent processing steps—to
a miRNA.44
In conclusion, our data extend the current view of sno/scaRNA
deregulation in cancer. In the context of MM, altered sno/scaRNA
expression could be consistent with the role that the activation of
the translational machinery may have in the pathogenesis of a
large fraction of MM. Indeed, the recent discovery of inactivating
mutations in genes involved in RNA processing, protein translation
and the unfolded protein response in MM patients has already led
to the suggestion that dysregulation of such processes may
represent oncogenic mechanisms in MM.45,46 Overall, sno/
scaRNAs deregulation in plasma cell dyscrasias adds a further
level of complexity to the heterogeneity of these forms and may
contribute to discover new biomarkers and altered molecular
pathways associated with the disease.
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